durlobactam

Also Known As:

(2s,5r)-2-carbamoyl-3-methyl-7-oxo-1,6-diazabicyclo(3.2.1)oct-3-en-6-yl sulfate; ETX2514; sulfuric acid, mono((2s,5r)-2-(aminocarbonyl)-3-methyl-7-oxo-1,6-diazabicyclo(3.2.1)oct-3-en-6-yl) ester

Networked: 11 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Aza Compounds: 3
  - Azabicyclo Compounds
    - durlobactam: 11
Heterocyclic Compounds: 198
- Bridged-Ring Heterocyclic Compounds
  - Heterocyclic Bridged Bicyclo Compounds
    - Azabicyclo Compounds
      - durlobactam: 11

Experts

1.	Miller, Alita A: 3 articles (01/2022 - 01/2021)
2.	Isaacs, Robin: 3 articles (01/2021 - 01/2019)
3.	O'Donnell, John: 3 articles (01/2021 - 01/2019)
4.	Moussa, Samir H: 2 articles (01/2021 - 01/2018)
5.	Shapiro, Adam B: 2 articles (01/2021 - 01/2021)
6.	Miller, Alita: 2 articles (01/2020 - 01/2018)
7.	Stone, Emily: 2 articles (01/2020 - 01/2019)
8.	Granata, Guido: 1 article (06/2022)
9.	Petrosillo, Nicola: 1 article (06/2022)
10.	Schiavone, Francesco: 1 article (06/2022)

Related Diseases

1.	Urinary Tract Infections (Urinary Tract Infection) 12/01/2022 - "Tebpipenem is an oral carbapenem with a recently completed phase III trial for complicated urinary tract infections while durlobactam-sulbactam represents a potential alternative for drug-resistant Acinetobacter baumannii . "
2.	Chronic Kidney Failure (Chronic Renal Failure) 01/01/2019 - "In summary, RI and ESRD had a predictable effect on the pharmacokinetic (PK) profile of durlobactam and sulbactam with no adverse effects on the safety/tolerability profile. " 01/01/2019 - "In healthy subjects and in those with mild or moderate renal impairment, the majority of durlobactam and sulbactam was excreted in the urine, while approximately 40% or less was excreted in urine in subjects with severe renal impairment or ESRD. " 01/01/2019 - "For subjects with ESRD and HD, 500-mg i.v. doses each of durlobactam and sulbactam were administered post-HD and pre-HD, with a 1-week washout between doses. " 01/01/2019 - "In subjects with ESRD, hemodialysis was effective at removing both durlobactam and sulbactam from plasma. " 01/01/2019 - "The dosing regimen of durlobactam-sulbactam will require adjustment in patients with severe renal insufficiency and in those with ESRD."
3.	Infections 06/07/2022 - "Durlobactam in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections: A Systematic Review." 01/01/2023 - "The present review describes the pharmacokinetic/pharmacodynamic (PK/PD) relationship associated with the activity of sulbactam and durlobactam established in nonclinical infection models with MDR Acinetobacter baumannii isolates. " 01/01/2023 - "The Pharmacokinetics/Pharmacodynamic Relationship of Durlobactam in Combination With Sulbactam in In Vitro and In Vivo Infection Model Systems Versus Acinetobacter baumannii-calcoaceticus Complex." 01/01/2022 - "To improve existing therapeutic regimens to address serious Mab infections, we evaluated the ability of durlobactam (DUR), a novel diazobicyclooctane β-lactamase inhibitor to restore in vitro susceptibilities in combination with β-lactams and provide a biochemical rationale for the activity of this compound. " 01/01/2022 - "However, avibactam is ineffective against Acinetobacter baumannii infections, unlike ETX2514. "
4.	Renal Insufficiency (Renal Failure) 01/01/2019 - "The dosing regimen of durlobactam-sulbactam will require adjustment in patients with severe renal insufficiency and in those with ESRD."
5.	Melioidosis 01/01/2021 - "pseudomallei by durlobactam, tested for blaPenA1 induction by SUL-DUR, and evaluated in vivo efficacy in a mouse model of melioidosis. "

Related Drugs and Biologics

1.	Sulbactam
2.	durlobactam
3.	Carbapenems (Carbapenem Antibiotics)
4.	Lactams
5.	Colistin (Coly-Mycin)
6.	avibactam

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)